Clinical trial of immunotherapy with paternal mononuclear cells for unexplained recurrent miscarriage

Abstract EN

The effect of immunotherapy with paternal leukocytes for the treatment of unexplained recurrent miscarriage is controversial.

To further investigate this we immunized S6 women with two or more previous miscarriages with approximately 0.5 × 109 paternal mononuclear cells.

Another 63 recurrent miscarries who conceived during the same period were used as controls.

There was no overall positive effect of paternal leukocyte transfusion but among women with three or-more miscarriages the success rate was significantly higher in the treatment group (p < 0.01) than the controls (83.9 % versus 51.7 %).

We found a significantly higher success rate (90 %) in the group immunized during pregnancy compared to (60 %) the group immunized before pregnancy (p < 0.05).

Conclusion : all immunization with paternal leukocytes showed a positive effect on the live birth rate in a subset of women with three or more miscarriages.

This treatment should not be offered to patients with a history of only two miscarriages and preferably it should be performed as early as possible during pregnancy.